FISH, Multiple Myeloma, 1q21
Also known as: Plasma Cell Myeloma
Use
Chromosomal abnormalities are detected in 80‑85% of myeloma patients. One or more extra copies of 1q21 has been associated with poor prognosis in patients with newly diagnosed myeloma, whether as a sole abnormality or in combination with other nonrandom abnormalities. Prognostic factors such as this are helpful to clinicians in determining therapy and predicting long‑term survival.
Special Instructions
Not provided.
Limitations
Not provided.
Methodology
Chromosomal / Cytogenetics (FISH)
Biomarkers
Result Turnaround Time
5-7 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
3 mL
Minimum Volume
1 mL
Container
culture transport medium; sodium heparin (green‑top, royal blue‑top, tan‑top) tube
Causes for Rejection
Do not freeze; specimen viability decreases during transit
Other tests from different labs that may be relevant
